MLC601 in vascular dementia: an efficacy and safety pilot study

BACKGROUND AND AIM: Vascular dementia (VaD) is the second most common cause of dementia and currently there is scarcity of therapies for VaD. We aimed to investigate the efficacy and safety of MLC601 in the treatment of VaD. METHODS: In this multicenter, pilot, randomized, double-blind trial, 82 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pakdaman, Hossein, Amini Harandi, Ali, Gharagozli, Koroush, Abbasi, Mehdi, Ghaffarpour, Majid, Ashrafi, Farzad, Delavar Kasmaei, Hosein, Amini Harandi, Asghar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634376/
https://www.ncbi.nlm.nih.gov/pubmed/29042785
http://dx.doi.org/10.2147/NDT.S145047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634376/
https://www.ncbi.nlm.nih.gov/pubmed/29042785
http://dx.doi.org/10.2147/NDT.S145047

Ejemplares similares